United States
Print page content Print
Increase text size Decrease text size
Text Size

SPIROVAC®

Leptospira Hardjo Bacterin

Spirovac® is for vaccination of healthy cattle four weeks of age or older, including those pregnant and/or lactating, for the prevention of infection by Leptospira borgpetersenii serovar hardjo-bovis, including reproductive and renal tract colonization, and urinary shedding for up to 12 months. Vaccination with Spirovac also aids in the prevention of fetal infection. Spirovac contains chemically inactivated whole cultures of L. borgpetersenii serovar hardjo type hardjo-bovis.

Expand All
  • Uses

    Spirovac is for vaccination of healthy cattle 4 weeks of age or older, including those pregnant and/or lactating, for the prevention of infection caused by Leptospira borgpetersenii serovar hardjo type hardjo-bovis, including reproductive and renal tract colonization, and urinary shedding for up to 12 months.  Vaccination with Spirovac also aids in the prevention of fetal infection. Spirovac contains chemically inactivated whole cultures of L. borgpetersenii serovar hardjo type hardjo-bovis.

    Key Features

    • Provides 12-month duration of immunity, resulting in less time and labor required for vaccination.
    • Safe for use in pregnant cows, enabling whole-herd vaccination.
    • Subcutaneous (SC) dose is 2mL followed by a second dose given four to six weeks later.
    • Annual revaccination with a single dose is recommended.

    Safety and Efficacy

    The safety of SPIROVAC was demonstrated in field studies representing different management practices in three different geographic locations in the United States. A total of 1,431 beef and dairy cattle were evaluated where 615 calves (224 calves were between four- and four and a half- weeks of age) and 816 cows (804 were pregnant) were vaccinated according to label recommendations. Safety in each trimester of pregnancy was established in dairy cows: 212 cows in the first trimester, 245 cows in the second trimester and 144 cows in the third trimester. No systemic reactions or significant injection site reactions were observed in vaccinated animals.

    The safety of an overdose of a Leptospira Pomona Bacterin (formulated as Spirovac but also containing L. interrogans serovar pomona) has been satisfactorily demonstrated in pregnant cattle. Ten pregnant cows in the first trimester of pregnancy were vaccinated with six times the recommended dose (twice the normal dose volume at three different injection sites). The cows were revaccinated in the same manner 28 days later. Despite the overdosing, only minor localized injection site reactions were observed, and no reaction exceeded 5 cm in diameter. No systemic reactions were observed and all ten cows were confirmed pregnant 30 days post-second vaccination.

    Researchers at the National Animal Disease Center (NADC) of the Agriculture Research Service (ARS), USDA, Ames, IA, conducted two separate studies evaluating the efficacy of Spirovac against the colonization of the urinary and reproductive tract of cattle when challenged with virulent strains of L. borgpetersenii serovar hardjo type hardjo-bovis.  The NADC challenge strains used in the studies are reliable in their ability to cause urinary shedding and represent the most common strains in the U.S. In the first study, heifers were vaccinated twice and challenged 16 weeks post-second vaccination with serovar hardjo type hardjo-bovis A by intraperitoneal inoculation or conjunctival instillation for three consecutive days.  Urine samples were collected weekly and heifers were euthanized 11-14 weeks post-challenge. Kidneys were examined for evidence of colonization. Leptospires were not detected in any of the urine or tissue samples from the Spirovac-vaccinated heifers, whereas six of eight nonvaccinated heifers shed leptospires in their urine and all eight had evidence of renal colonization.

    In the second study, 12 Spirovac-vaccinated and 12 nonvaccinated heifers were challenged 18 weeks post-vaccination by instillation of either serovar hardjo type hardjo-bovis type A or type hardjo-bovis B into the conjunctival sac and vagina. Cattle were monitored to detect urinary shedding of serovar hardjo for 8 weeks after challenge and the presence of leptospires in the uterus and oviducts was determined at necropsy. Urinary shedding of serovar hardjo was not detected in any (0 of 12) of the cattle vaccinated with Spirovac. In contrast, nonvaccinated cattle became infected and shed serovar hardjo in their urine (12 of 12).

    Vaccinated cattle also were protected from colonization of the reproductive tract, whereas leptospires were detected in the uterus or oviducts of 10 of 12 control heifers.
    The efficacy of Spirovac as an aid in the prevention of placental and fetal infection was established in a study conducted by researchers at the NADC and Michigan State University.  Heifers were vaccinated two times prior to breeding, and challenged at mid-gestation with virulent L. borgpetersenii serovar hardjo by conjunctival and vaginal instillation. Heifers were monitored for urinary shedding until calving. Heifers and calves and cows were euthanized as soon as possible after parturition and urine samples, maternal kidney, placenta and fetal tissues were examined to detect the presence of leptospires. Urinary shedding of serovar hardjo was detected in all (8 of 8) nonvaccinated control heifers and in none (0 of 16) of the vaccinated heifers after challenge. Leptospires were detected in the placenta or fetal tissues of five of eight control cattle, whereas leptospires were not detected in any of the placenta or fetal tissues of the 16 Spirovac-vaccinated heifers. Therefore, vaccination with Spirovac prevented fetal infection in heifers challenged at mid-gestation with L. borgpetersenii serovar hardjo.
    To determine the efficacy of a Leptospira Hardjo-Pomona Bacterin formulated as Spirovac but also containing L. interrogans serovar pomona) in young calves with maternally derived antibodies, a group of 12 calves from cows previously vaccinated were divided into four equal groups, with the first dose of Spirovac given at either four, six, 10, or 18 weeks of age and the second dose given four weeks after the first dose according to label recommendations. Seven seronegative calves from unvaccinated cows were used as a control group. All calves were challenged at 30-32 weeks of age. Microscopic agglutination titers (MAT) prevaccination ranged from 2 - 25, with maternal antibody titers observed for up to 13 weeks after birth. MAT titers were significantly higher in controls than vaccinates post-challenge. Serological titer rise in vaccinates were inversely proportional to prevaccination titers. Leptospiruria was not detected in any of the vaccinated calves but occurred in 71 percent of control calves within 21 days of challenge and in all controls by 35 days. This study showed that young calves vaccinated as early as four weeks of age were protected against a virulent challenge with L. borgpetersenii serovar hardjo type hardo-bovis.

    In a study conducted by researchers at the University of Massachusetts, NADC, and Michigan State University, Spirovac was demonstrated to induce a strong, sustained cell-mediated immune response against Leptospira borgpetersenii serovar hardjo-type hardjo-bovis.  Spirovac induced production of gamma interferon and strong antigen-specific proliferative responses by peripheral blood mononuclear cells beginning two months after the first dose of vaccine and continuing for the seven-month study period. These responses were absent from nonvaccinated control cattle. A cell-mediated immune response is associated with protection against Leptospira borgpetersenii serovar hardjo type hardjo-bovis.


    Duration-of-immunity study

    Twelve months duration-of-immunity was shown in a 54-week vaccination-challenge study. Eighteen seven- to 10-month-old calves were divided into two groups. Nine calves were vaccinated twice with Spirovac according to label recommendations at four-week intervals and nine calves were held as controls. The eighteen calves were housed together, held in isolation for 54 weeks, and subsequently challenged with L. borgpetersenii serovar hardjo type hardjo-bovis. Spirovac was shown to protect 100 percent of the vaccinated calves against urinary shedding (leptospiruria). It was concluded that Spirovac could provide protection for at least 12 months when administered according to label recommendations to healthy animals.

  • Directions

    1. General directions: Vaccination of healthy cattle is recommended. Shake well. Aseptically administer 2 mL subcutaneously. In accordance with Beef Quality Assurance guidelines, this product should be administered subcutaneously (under the skin) in the neck.
    2. Primary vaccination: Healthy cattle should receive two doses administered four to six weeks apart.  When used as an aid in preventing fetal infection, administer the second dose at least two weeks prior to breeding.
    3. Revaccination: Annual revaccination with a single dose is recommended.
    4. Good animal husbandry and herd health management practices should be employed.

    Packaging

    10- and 50-dose vials

  • Precautions

    1. Store away from light at 2°–7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
    2. Use entire contents when first opened.
    3. Sterilized syringes and needles should be used to administer this vaccine.
    4. Do not vaccinate within 21 days before slaughter.
    5. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
    6. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.